Research confirms benefits of side-actuated nasal spray

Published: 8-Feb-2010
Ingredients Drug Delivery Research & Development Pharmaceutical

Valois Pharma's side-actuated nasal spray has excellent ergonomics, is comfortable to handle and easy to actuate, research by the French pharmaceutical company reveals.

Valois Pharma's side-actuated nasal spray has excellent ergonomics, is comfortable to handle and easy to actuate, research by the French pharmaceutical company reveals.

The side-actuated nasal spray consists of a standard actuator coupled with a customisable shell and cap.

The research, carried out in the UK last November involving 10 regular nasal spray users, as well as six doctors (GPs and ENT specialists), showed that the side-actuated delivery device has the three advantages mentioned above.

Patients also thought a slightly longer nozzle would improve the placement of the device in the nostril when the device is actuated, and Valois will further investigate this.

The company says new user research will be carried out in the US in the coming months to confirm the results of the current study.




See more

You may also like

Drug Delivery

Nuvec nanoparticles successfully target lung cancer cells

Read more
N4 Pharma announces further details of its collaboration with SRI International to investigate the targeted delivery of RNA into cells using Nuvec

Trending Articles

  1. Biotech Fluidics AB At Biotech Fluidics, our aim is to help you make your analytical work more effective and reliable.
  2. Medicines Discovery Catapult and Crown Bioscience forge global alliance to advance radiopharmaceutical innovation The partnership will create an integrated translational biology platform to accelerate the development of next-generation radiopharmaceuticals for cancer diagnosis and treatment
  3. FDA makes groundbreaking decision to waive clinical efficiency studies for monoclonal antibody biosimilars The University of Illinois secured the first-ever FDA acceptance to waive clinical efficiency studies (CESs) for the biological drugs
  4. New TXA autoinjector could save lives in severe bleeding emergencies In a breakthrough for emergency and trauma medicine, new study results show that TXA autoinjectors deliver lifesaving treatment for severe bleeding in under five minutes and without the need for medical expertise
  5. Debunking the myths of HPMC adoption Adopting new products, formulations and ways of working can be a challenge for industries as regulated as pharmaceuticals, writes Dr Subhashis Chakraborty, General Manager, Head of Global Product Management, at ACG Capsules

Upcoming event

CPHI Frankfurt 2025

28–30 October 2025 | Exhibition | Frankfurt, Germany See all

You may also like

Drug Delivery

Nuvec nanoparticles successfully target lung cancer cells

N4 Pharma announces further details of its collaboration with SRI International to investigate the targeted delivery of RNA into cells using Nuvec
Drug Delivery

Shimadzu enhances dual ion source technology with compact LCMS-2050

The system combines high-speed analysis, energy efficiency, and advanced DUIS capability in a compact design
Manufacturing

Titan develops bespoke calibration rig for ultra-low flow measurement

Company designs state-of-the-art system to support next-generation ultrasonic flowmeters
Regulatory

CHMP recommends Sanofi and Regeneron’s Dupixent to treat chronic spontaneous urticaria in EU

If approved, it would be the first targeted CSU therapy in the EU in more than a decade, supported by Phase III LIBERTY-CUPID data showing significant itch and hive reduction at 24 weeks
Research & Development

University of Liverpool scientists unveil Novltex, a powerful new antibiotic against superbugs

The groundbreaking synthetic antibiotic is effective against multidrug-resistant bacteria such as MRSA and Enterococcus faecium, offering a promising new weapon in the global fight against antimicrobial resistance
Research & Development

Lilly’s oral GLP-1 orforglipron outperforms semaglutide in Phase III head-to-head trial

The results highlight orforglipron’s potential as a once-daily oral therapy to help more patients achieve near-normal glucose levels and meaningful weight reduction
Drug Delivery

Piramal Pharma Solutions augments formulation capabilities with the addition of new Korsch XM-12 bilayer tablet press at its Morpeth, UK facility

This tablet press will provide the facility’s Formulation Development Team with an important tool for developing fixed dose combinations and modified release drug delivery. Piramal Pharma Solutions has implemented robust training protocols to ensure safe operation and high-quality output from the XM-12
Subscribe now